An experimental drug poised to become the world's leading treatment for multiple sclerosis got investors excited about this Massachusetts-based drug-maker. Shares of Biogen Idec surged after studies showed the effectiveness of BG-12, which analysts estimate could generate up to $3 billion in annual sales.
Under relatively new CEO George Scangos, Biogen reported robust earnings. For 2011, profits rose by 23% to $1.23 billion or $5.04 per share. And Scangos was handsomely rewarded for that
performance. He earned $11.3 million in salary, bonus and stock awards.